File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3389/fonc.2020.01294
- Scopus: eid_2-s2.0-85089809419
- PMID: 32850403
- WOS: WOS:000563472400001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Resurrection of oral arsenic trioxide for treating acute promyelocytic leukaemia: A historical account from bedside to bench to bedside
Title | Resurrection of oral arsenic trioxide for treating acute promyelocytic leukaemia: A historical account from bedside to bench to bedside |
---|---|
Authors | |
Keywords | Oral arsenic trioxide Acute promyelocitic leukaemia History Pharmacokinetics Clinical applications |
Issue Date | 2020 |
Publisher | Frontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/oncology |
Citation | Frontiers in Oncology, 2020, v. 10, article no. 1294 How to Cite? |
Abstract | Various forms of arsenic were used in China and elsewhere for over 5,000 years. Following the initial success of intravenous arsenic trioxide (i.v. As2O3), we revived an oral formulation of pure As2O3 in 1998 for the treatment of acute promyelocytic leukemia (APL). We were the first to produce a 1 mg/ml oral-As2O3 solution and showed that it had comparable bioavailability to i.v. As2O3. Moreover, we also reported that intracellular arsenic concentrations were considerably higher than the corresponding plasma values. Our oral-As2O3 was patented internationally and registered in Hong Kong for the treatment of APL. Safety, tolerability and clinical efficacy was confirmed in long-term follow-up studies. We have extended the use of oral-As2O3 to frontline induction of newly diagnosed APL. With these findings, we are moving toward an era of completely oral and chemotherapy-free management of APL. |
Persistent Identifier | http://hdl.handle.net/10722/284577 |
ISSN | 2023 Impact Factor: 3.5 2023 SCImago Journal Rankings: 1.066 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kumana, CR | - |
dc.contributor.author | Mak, R | - |
dc.contributor.author | Kwong, YL | - |
dc.contributor.author | Gill, H | - |
dc.date.accessioned | 2020-08-07T08:59:37Z | - |
dc.date.available | 2020-08-07T08:59:37Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Frontiers in Oncology, 2020, v. 10, article no. 1294 | - |
dc.identifier.issn | 2234-943X | - |
dc.identifier.uri | http://hdl.handle.net/10722/284577 | - |
dc.description.abstract | Various forms of arsenic were used in China and elsewhere for over 5,000 years. Following the initial success of intravenous arsenic trioxide (i.v. As2O3), we revived an oral formulation of pure As2O3 in 1998 for the treatment of acute promyelocytic leukemia (APL). We were the first to produce a 1 mg/ml oral-As2O3 solution and showed that it had comparable bioavailability to i.v. As2O3. Moreover, we also reported that intracellular arsenic concentrations were considerably higher than the corresponding plasma values. Our oral-As2O3 was patented internationally and registered in Hong Kong for the treatment of APL. Safety, tolerability and clinical efficacy was confirmed in long-term follow-up studies. We have extended the use of oral-As2O3 to frontline induction of newly diagnosed APL. With these findings, we are moving toward an era of completely oral and chemotherapy-free management of APL. | - |
dc.language | eng | - |
dc.publisher | Frontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/oncology | - |
dc.relation.ispartof | Frontiers in Oncology | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Oral arsenic trioxide | - |
dc.subject | Acute promyelocitic leukaemia | - |
dc.subject | History | - |
dc.subject | Pharmacokinetics | - |
dc.subject | Clinical applications | - |
dc.title | Resurrection of oral arsenic trioxide for treating acute promyelocytic leukaemia: A historical account from bedside to bench to bedside | - |
dc.type | Article | - |
dc.identifier.email | Kwong, YL: ylkwong@hkucc.hku.hk | - |
dc.identifier.email | Gill, H: gillhsh@hku.hk | - |
dc.identifier.authority | Kwong, YL=rp00358 | - |
dc.identifier.authority | Gill, H=rp01914 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.3389/fonc.2020.01294 | - |
dc.identifier.pmid | 32850403 | - |
dc.identifier.pmcid | PMC7418518 | - |
dc.identifier.scopus | eid_2-s2.0-85089809419 | - |
dc.identifier.hkuros | 312425 | - |
dc.identifier.volume | 10 | - |
dc.identifier.spage | article no. 1294 | - |
dc.identifier.epage | article no. 1294 | - |
dc.identifier.isi | WOS:000563472400001 | - |
dc.publisher.place | Switzerland | - |
dc.identifier.issnl | 2234-943X | - |